A mixed methods study of the awareness and management of familial hypercholesterolaemia in Irish general practice

A mixed methods study of the awareness and management of familial hypercholesterolaemia in Irish general practice

IntroductionFamilial Hypercholesterolemia (FH) is one of the most common genetic disorders, with an estimated global prevalence of 1:200-500, which leads to premature cardiovascular disease. Nevertheless, public and professional awareness of FH is often lacking, with an estimated 20,000 largely undi...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Robyn Homeniuk, Joseph Gallagher, Claire Collins
Format:	Artykuł
Język:	English
Wydane:	Frontiers Media S.A. 2022-10-01
Seria:	Frontiers in Medicine
Hasła przedmiotowe:	primary care general practice familial hypercholesterolaemia hyperlipidemia record screening LDL cholesterol
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fmed.2022.1016198/full

Podobne zapisy

Overview of a collaborative global effort to address the burden of familial hypercholesterolaemia
od: Alexander R.M. Lyons, i wsp.
Wydane: (2024-03-01)

Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis
od: Anastasia V. Poznyak, i wsp.
Wydane: (2022-10-01)

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
od: Vallejo-Vaz, Antonio J., i wsp.
Wydane: (2020)

How do the experiences and beliefs of adults and children with heterozygous familial hypercholesterolaemia influence their adherence to treatment? A systematic review of qualitative evidence protocol
od: Fiona J. Kinnear, i wsp.
Wydane: (2018-08-01)

Suppression of diet-induced hypercholesterolaemia by saponins from Panax notoginseng in rats
od: Jian-Hong Wu, i wsp.
Wydane: (2013-07-01)

Postprandial changes in gene expression of cholesterol influx and efflux mediators after intake of SFA compared with n-6 PUFA in subjects with and without familial hypercholesterolaemia: secondary outcomes of a randomised controlled trial
od: Linn K. L. Øyri, i wsp.
Wydane: (2019-01-01)

Screening for potential familial hypercholesterolaemia in general practice: an observational study on prevalence and management
od: Stefan Mülverstedt, i wsp.
Wydane: (2021-04-01)

Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective
od: Gerald F. Watts, i wsp.
Wydane: (2021-06-01)

International Atherosclerosis Society Roadmap for Familial Hypercholesterolaemia
od: Gerald F. Watts, i wsp.
Wydane: (2024-01-01)

Dietary intervention for children and adolescents with familial hypercholesterolaemia
od: Maria Elena Capra, i wsp.
Wydane: (2023-06-01)

Familial hypercholesterolaemia
od: D.J. Blom
Wydane: (2011-01-01)

Genetics in familial hypercholesterolaemia – from genetic research to new guidelines
od: Edyta Kinga Prokop, i wsp.
Wydane: (2019-04-01)

Evolocumab-induced delayed skin hypersensitivity reaction in a patient with familial hypercholesterolaemia
od: Grzegorz Porebski, i wsp.
Wydane: (2024-02-01)

Triple-combined hypolipidaemic therapy in familial hypercholesterolaemia: clinical cases
od: Svetlana A. Chepurnenko, i wsp.
Wydane: (2021-10-01)

Inclisiran for the treatment of hypercholesterolaemia
od: Joel C Marrs, i wsp.
Wydane: (2024-11-01)

Irbesartan; An Antihypertensive Drug Reduces LDL-Cholesterol in Diet Induced Hyperlipidemic Rabbits
od: Sabeen Shakir , Akbar Waheed , Noureen Hafeez
Wydane: (2016-09-01)

Real-world data on treatment patterns in at least high cardiovascular risk patients on dual and triple lipid lowering therapy in a Hellenic nationwide e-prescription database
od: Dimitrios Terentes-Printzios, i wsp.
Wydane: (2024-06-01)

Children and young adults with familial hypercholesterolaemia (FH) have healthier food choices particularly with respect to dietary fat sources compared with non-FH children
od: Ingunn Molven, i wsp.
Wydane: (2013-01-01)

A UK multicentre audit of the management of patients with primary hypercholesterolaemia or mixed dyslipidaemia with bempedoic acid against published lipid-lowering treatment targets
od: Sudarshan Ramachandran, i wsp.
Wydane: (2024-08-01)

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation
od: P Sharma, i wsp.
Wydane: (2012-03-01)

Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review
od: Noor Shafina Mohd Nor, i wsp.
Wydane: (2019-04-01)

New Insights into the Role of Coenzyme Q10 in Serum LDLCholesterol Reduction
od: Sabeen Shakir, Zunnera Rashid, Naureen Hafeez
Wydane: (2017-03-01)

Evaluating a clinical tool (FAMCAT) for identifying familial hypercholesterolaemia in primary care: a retrospective cohort study
od: Ralph K Akyea, i wsp.
Wydane: (2020-11-01)

Enhanced status of inflammation and endothelial activation in subjects with familial hypercholesterolaemia and their related unaffected family members: a case control study
od: Thuhairah Rahman, i wsp.
Wydane: (2017-04-01)

Selective screening for familial hypercholesterolemia in Austrian children - first year results
od: Alexandra Kreissl, i wsp.
Wydane: (2019-06-01)

Elevated remnant cholesterol and non-HDL cholesterol concentrations from real-world laboratory results: a cross-sectional study in Southeast Asians
od: Wann Jia Loh, i wsp.
Wydane: (2024-02-01)

Early Prevention of Atherosclerosis: Detection and Management of Hypercholesterolaemia in Children and Adolescents
od: Cristina Pederiva, i wsp.
Wydane: (2021-04-01)

Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
od: Nadeem Qureshi, i wsp.
Wydane: (2023-10-01)

Sex specific analysis of patients with and without reported statin intolerance referred to a specialized outpatient lipid clinic
od: Maximilian A. Muck, i wsp.
Wydane: (2024-09-01)

The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk
od: Natalie Schellack, i wsp.
Wydane: (2016-01-01)

Evaluation of Reference Genes for Quantitative PCR in Four Tissues from Rabbits with Hypercholesterolaemia
od: Zhen Zhang, i wsp.
Wydane: (2019-12-01)

Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia
od: R Dariolo
Wydane: (2008-07-01)

Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community
od: Hayato Tada, i wsp.
Wydane: (2020-11-01)

Detection of Lipoprotein X (LpX): A challenge in patients with severe hypercholesterolaemia
od: Ćwiklińska Agnieszka, i wsp.
Wydane: (2020-01-01)

Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial
od: Hong Tan, i wsp.
Wydane: (2023-02-01)

Prevalence and distributions of severely elevated low-density lipoprotein cholesterol (LDL-c) according to age, gender and clinic location among patients in the Malaysian primary care
od: Johanes Dedi Kanchau, i wsp.
Wydane: (2024-05-01)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
od: A. V. Blokhina, i wsp.
Wydane: (2022-01-01)

Identification of liver CYP51 as a gene responsive to circulating cholesterol in a hamster model
od: Haiqiu Huang, i wsp.
Wydane: (2016-01-01)

The effect of DALI lipid apheresis in the prognosis of homozygous familial hypercholesterolemia: Seven patients' experience at a DALI apheresis center
od: Muhammet Bulut, i wsp.
Wydane: (2020-01-01)

Effect of Hyperlipidemia Patterns on Complete Blood Cell Count: A Case-Control Study
od: Azam Alizamir, i wsp.
Wydane: (2018-03-01)